Top Page
United Therapeutics
(NASDAQ:UTHR)
United Therapeutics (UTHR) vs. SPDR S&P 500 ETF (SPY)
United Therapeutics Business Overview & Revenue Model
United Therapeutics Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataUnited Therapeutics Earnings Call Summary
United Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.13B | 2.88B | 2.33B | 1.94B | 1.69B | 1.48B |
| Gross Profit | 2.77B | 2.57B | 2.07B | 1.79B | 1.56B | 1.38B |
| EBITDA | 1.71B | 1.65B | 1.39B | 1.04B | 736.80M | 646.30M |
| Net Income | 1.27B | 1.20B | 984.80M | 727.30M | 475.80M | 514.80M |
Balance Sheet | ||||||
| Total Assets | 7.35B | 7.36B | 7.17B | 6.04B | 5.17B | 4.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.77B | 3.27B | 2.99B | 2.84B | 1.93B | 1.83B |
| Total Debt | 0.00 | 300.00M | 700.00M | 800.00M | 800.00M | 800.00M |
| Total Liabilities | 760.90M | 920.00M | 1.18B | 1.25B | 1.21B | 1.22B |
| Stockholders Equity | 6.59B | 6.44B | 5.98B | 4.80B | 3.96B | 3.40B |
Cash Flow | ||||||
| Free Cash Flow | 1.12B | 1.08B | 747.60M | 663.70M | 477.40M | 696.40M |
| Operating Cash Flow | 1.56B | 1.33B | 978.00M | 802.50M | 598.20M | 755.70M |
| Investing Cash Flow | -446.90M | 417.20M | -719.60M | -811.50M | -486.90M | -738.50M |
| Financing Cash Flow | -1.32B | -1.25B | -11.90M | 75.40M | 44.80M | -16.90M |
United Therapeutics Technical Analysis
United Therapeutics Risk Analysis
United Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $20.65B | 17.78 | 30.39% | ― | 18.09% | 3563.21% | |
79 Outperform | $19.27B | 17.21 | 20.04% | ― | 13.50% | 17.16% | |
76 Outperform | $10.94B | 17.18 | 30.56% | ― | 9.93% | 54.33% | |
74 Outperform | $17.80B | 14.19 | 26.08% | ― | 23.25% | 64.46% | |
73 Outperform | $9.96B | 19.28 | 9.07% | ― | 12.31% | 60.21% | |
61 Neutral | $12.07B | ― | ― | ― | 55.77% | 46.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
United Therapeutics Corporate Events
United Therapeutics Corporation is a biotechnology company that focuses on the development of pharmaceutical therapies and technologies to address unmet medical needs, particularly in the area of pulmonary diseases and organ transplantation. As a public benefit corporation, it aims to provide innovative solutions while fulfilling its public benefit purpose.
United Therapeutics Corp’s recent earnings call painted a picture of robust financial health and strategic growth, with positive sentiments echoing throughout the discussion. The company showcased strong financial performance, successful clinical trials, and strategic growth initiatives, although some uncertainties linger regarding market competition and regulatory processes.
Study Overview: United Therapeutics Corp. is conducting a study titled ‘An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)’. The study aims to evaluate the long-term safety and tolerability of inhaled treprostinil in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis. This research is significant as it addresses the need for effective long-term treatments for these serious lung conditions.
Study Overview: United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF).’ The study aims to evaluate the safety and efficacy of inhaled treprostinil in patients with progressive pulmonary fibrosis over a 52-week period. This research is significant as it targets a serious lung condition with limited treatment options.
The MOMENTOUS Study, officially titled ‘Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension,’ aims to evaluate the effectiveness of an ECG-based AI device in predicting the risk of undiagnosed pulmonary hypertension in patients with interstitial lung disease (ILD). This study is significant as it could enhance early diagnosis and treatment strategies for pulmonary hypertension, potentially improving patient outcomes.
United Therapeutics Corp. is currently recruiting for the DeciPHer-ILD study, a real-world patient registry focusing on Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). The study aims to gather comprehensive data on patients with PH-ILD to better understand the condition and improve treatment strategies. This registry is significant as it could lead to enhanced patient outcomes and inform future therapeutic developments.
Study Overview: United Therapeutics Corp. is conducting a study titled EXPAND: A Prospective Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With End-stage Renal Disease (ESRD). This study aims to assess the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either ineligible for conventional kidney transplantation or are on a transplant waitlist with a high risk of not receiving a transplant within five years. The study’s significance lies in its potential to offer a new treatment option for patients with limited alternatives.
United Therapeutics Corp. is conducting a study titled ‘Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER).’ The study aims to evaluate screening strategies for pulmonary hypertension in patients with interstitial lung disease, which could lead to earlier detection and treatment of this serious condition.
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)’. The study aims to assess the long-term safety and efficacy of Ralinepag, a drug designed to treat PAH, a serious cardiovascular condition.
On September 2, 2025, United Therapeutics announced positive results from the TETON-2 clinical study of Tyvaso® for idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, showing significant improvement in forced vital capacity compared to placebo, and demonstrated benefits across various subgroups. These results could potentially reshape IPF treatment and offer new hope for patients, as the company plans to use this data to support a supplemental New Drug Application to the FDA.
The most recent analyst rating on (UTHR) stock is a Buy with a $347.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
United Therapeutics Corp. is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF). The study aims to evaluate the safety and efficacy of inhaled treprostinil in treating progressive pulmonary fibrosis (PPF) over a 52-week period, which is significant for advancing treatment options for this condition.
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF).’ The study aims to evaluate the safety and efficacy of inhaled treprostinil in patients with progressive pulmonary fibrosis over a 52-week period, highlighting its potential significance in treating this condition.
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)’. The study aims to evaluate the safety and efficacy of inhaled treprostinil in patients with progressive pulmonary fibrosis over a 52-week period, which is significant for advancing treatment options for this condition.
Study Overview: United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2).’ The study aims to evaluate the efficacy and safety of inhaled treprostinil in improving lung function, specifically measuring the change in forced vital capacity (FVC) over 52 weeks, compared to a placebo. This research is significant as it targets idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options.
On August 1, 2025, United Therapeutics Corporation announced the initiation of a $1 billion accelerated share repurchase program, reflecting confidence in its stock value and future growth prospects. The company entered into agreements with Citibank to repurchase shares, with settlements expected in late 2025 and early 2026, highlighting a strategic move to balance investment in growth with returning capital to shareholders.
The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
United Therapeutics Corp. is conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis. The study aims to evaluate the effectiveness of inhaled treprostinil compared to a placebo in improving lung function, as measured by forced vital capacity (FVC), over a 52-week period in patients with idiopathic pulmonary fibrosis (IPF).
United Therapeutics Corp. is conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF). The study aims to evaluate the safety and efficacy of inhaled treprostinil in patients with progressive pulmonary fibrosis over a 52-week period. This research is significant as it seeks to provide a new treatment option for a challenging condition.
The DelIVery for Pulmonary Arterial Hypertension (PAH) Clinical Study aims to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter, used with the SynchroMed® II Implantable Infusion System to deliver Remodulin® (treprostinil) Injection. This study is significant as it seeks to improve patient convenience and reduce complications associated with external delivery systems for PAH, a severe chronic condition.
United Therapeutics Corp.’s recent earnings call painted a picture of strong performance and growth, tempered by some concerns. The company reported record revenue growth and significant advancements in its pipeline, reflecting a generally positive sentiment. However, there were some apprehensions regarding the TPIP Phase IIb PAH data and the potential market competition. The authorization of a substantial share buyback demonstrates confidence in the company’s future prospects.
United Therapeutics Corporation, a public benefit biotech company, specializes in developing pharmaceutical therapies and technologies to expand transplantable organ availability, with a focus on treating pulmonary diseases.
Study Overview: United Therapeutics Corp. is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF). The study aims to evaluate the safety and efficacy of inhaled treprostinil in treating progressive pulmonary fibrosis (PPF) over a 52-week period, which is significant for advancing treatment options for this condition.
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis.’ The study aims to assess the efficacy and safety of inhaled treprostinil compared to a placebo in improving lung function, specifically the forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF) over a 52-week period. This research is significant as it explores a potential treatment for a condition with limited therapeutic options.